Compare ACADIA Pharmaceuticals Inc. (ACAD) vs US Global Jets ETF (JETS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs US Global Jets ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while US Global Jets ETF trades at $31.68. The key difference: US Global Jets ETF is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | JETS | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Sector/Thematic |
52-Week High | $28.06 | $33.34 |
52-Week Low | $20.06 | $23.12 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
JETS trades at $33.34, up 0.42% with a bullish technical outlook from moving averages but overbought RSI signals. The ETF faces headwinds from soaring airline fuel costs, which jumped 85% in May to $6.7 billion (Reuters, 2026-07-07), pressuring profitability across the sector. Recent news highlights industry challenges including engine maker delays and fare pressures, though falling oil prices offer some relief.
Outlook remains cautious due to cyclical risks and fuel volatility; the ETF provides diversified airline exposure but requires monitoring of margin compression. Investment opportunity hinges on oil price trends and travel demand recovery, with significant downside risk if cost pressures persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →
